The George Institute for Global Health, UNSW, Sydney, Australia.
Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Curr Hypertens Rep. 2020 Aug 27;22(9):65. doi: 10.1007/s11906-020-01069-7.
To summarise the advances that have been made from 2017 in dual, triple, and quadruple low-dose combination therapy for treating high blood pressure.
Many people require multiple blood pressure lowering medicines to achieve target blood pressures, and initiating treatment with combination blood pressure lowering therapy is being increasingly investigated and recommended. Low-dose combinations of blood pressure lowering provide more effective blood pressure lowering, with fewer adverse events. Recent advances include listing of four dual combinations on the WHO Essential Medicines List, completion of a triple half-dose combination trial, and a pilot of quadruple quarter-dose combination, and recent cardiovascular polypill trials have included two blood pressure lowering medicines at low dose. These trials all demonstrated improvements in achieving blood pressure targets with low-dose combination therapy. Low-dose combination therapy is a promising option for initial treatment of hypertension that appears to be safe and effective. Larger trials of triple and quadruple low-dose combination therapy in multiple locations are underway and should provide stronger evidence of efficacy as well as information on the side effect profile.
总结 2017 年以来,用于治疗高血压的双联、三联和四联低剂量组合疗法的进展。
许多人需要多种降压药物才能达到目标血压,并且越来越多地研究和推荐起始降压联合治疗。降压的低剂量组合提供更有效的降压作用,且不良事件更少。最近的进展包括将四种双联组合列入世界卫生组织基本药物清单,完成了三联半剂量组合试验,以及四重四分之一剂量组合的试点,最近的心血管复方药试验都包含了两种低剂量的降压药物。这些试验都表明,低剂量组合疗法在实现血压目标方面具有优势。低剂量组合疗法是治疗高血压的一种很有前途的初始治疗选择,似乎安全且有效。正在多个地点进行更大规模的三联和四联低剂量组合疗法试验,应该能提供更有力的疗效证据以及关于副作用特征的信息。